Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 1—January 2015

Prisoners Treated for Hepatitis C with Protease Inhibitor, New York, USA, 2012

Harish Moorjani, Carl Koenigsmann, Min Jung Kim, and Anne C. SpauldingComments to Author 
Author affiliations: New York Medical College, Valhalla, New York, USA (H. Moorjani); New York State Department of Corrections and Community Supervision, Albany, New York, USA (C. Koenigsmann); Emory University, Atlanta, Georgia, USA (M.J. Kim, A.C. Spaulding)

Main Article


Outcomes of 50 prisoners treated for hepatitis C* within the New York State Department of Corrections and Community Services, 2012–2013†

Outcome No. (%) Metavir staging of fibrosis
No. stage 1–3 (%) No. stage 4 (%)
Disenrolled 2 (4) 1 (2) 1 (11)
Treatment failed 4 (8) 2 (5) 2 (22)
Sustained viral response 44 (88) 38 (93) 6 (67)
Early rapid viral response 34 (68) 31 (76) 3 (33)
Total NA 41 9

*Treated with telaprevir, pegylated interferon, and ribavirin.
†NA, not applicable.

Main Article

Page created: December 19, 2014
Page updated: December 19, 2014
Page reviewed: December 19, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.